U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07546149) titled 'A Multiple Ascending Dose Study of LW402 in Healthy Volunteers' on Sept. 23, 2025.
Brief Summary: This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability and pharmacokinetics of multiple doses of LW402 tablets in healthy volunteers.
Study Start Date: Oct. 15, 2025
Study Type: INTERVENTIONAL
Condition:
Safety Evaluation of Escalating Doses
Intervention:
DRUG: Experimental
LW402 Tablets
DRUG: Placebo
LW402 Placebo Tablets
Recruitment Status: COMPLETED
Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
Disclaimer: Curated by HT Syndication....